4
ABT
ABBOTT LABORATORIES · Health Care
Consensus score 4/100 · #116 this quarter · tier-weighted across tracked managers
→NeutralPrice action since filingas of 2026-09-30
vs 50-day avg
+1.3%
21-day momentum
-14.9%
recent volume
0.68×
13F filings lag ~45 days; this is current price/volume action on top — a technical read, not a prediction.
S4· DecliningStage Analysis · Weinstein
vs 30-wk avg
-7.3%
30-wk MA slope
-2.9%
rel. strength
-27.3
52-wk range
30%
Declining — below a falling 30-week trend, lagging the market. Weinstein says avoid. Based on the 30-week (150-day) moving average + slope, Mansfield relative strength vs SPY, and volume. Technical read, not advice.
Holders
4
tracked managers
New this Q
1
opened a position
Avg weight
1.0%
of their portfolios
Combined value
$79M
held, at quarter-end
Who’s holding it Q2 2026, by position size
| Manager | Position size | Value | Change |
|---|---|---|---|
| Southeastern / Longleaf Deep value | 4.0% | $76M | NEW |
| Gardner Russo & Quinn Graham/global value | 0.0% | $1M | HOLD |
| Horizon Kinetics Franchise/inflation | 0.0% | $882K | ADD |
| Polen Capital Quality growth | 0.0% | $286K | TRIM |
Position size = share of that manager’s reported long US-equity portfolio. The consensus score weights each holder by quality tier, position size, and whether they were buying or trimming — then discounts very crowded names. It measures agreement among these managers, not expected return.